Literature DB >> 16427782

Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study.

E Mercuri1, S Messina, R Battini, A Berardinelli, P Boffi, R Bono, C Bruno, N Carboni, C Cini, F Colitto, A D'Amico, C Minetti, M Mirabella, T Mongini, L Morandi, N Dlamini, S Orcesi, M Pelliccioni, M Pane, A Pini, A V Swan, M Villanova, G Vita, M Main, F Muntoni, E Bertini.   

Abstract

The aim of this study was to validate the Hammersmith functional motor scale for children with spinal muscular atrophy in a large cohort of 90 non-ambulant children with spinal muscular atrophy type 2 or 3. All had a baseline assessment (T0) and were reassessed either at 3 months (T1) (n = 66) or at 6 months (T2) (n = 24). Inter-observer reliability, tested on 13 children among 3 examiners, was > 95%. Of the 66 children examined after 3 months 4 had adverse effects in between assessments and were excluded from the analysis. Forty-two (68%) of the remaining 62 reassessed had no variation in scores between T0 and T1 and 13 (21%) were within +/- 1 point. 9 (37.5%) of the 24 children reassessed after 6 months had no variation in scores between T0 and T2 and another 9 (37.5%) had variations within +/- 1 point. Our study confirms previous observations of the reliability of the scale and helps to establish a baseline for assessing changes of functional ability over 3 and 6 month intervals. This information can be valuable in view of therapeutic trials.

Entities:  

Mesh:

Year:  2006        PMID: 16427782     DOI: 10.1016/j.nmd.2005.11.010

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  15 in total

1.  Issues in SMA clinical trial design. The International Coordinating Committee (ICC) for SMA Subcommittee on SMA Clinical Trial Design.

Authors:  P Kaufmann; F Muntoni
Journal:  Neuromuscul Disord       Date:  2007-02-14       Impact factor: 4.296

2.  Rasch analysis of clinical outcome measures in spinal muscular atrophy.

Authors:  Stefan J Cano; Anna Mayhew; Allan M Glanzman; Kristin J Krosschell; Kathryn J Swoboda; Marion Main; Birgit F Steffensen; Carole Bérard; Françoise Girardot; Christine A M Payan; Eugenio Mercuri; Elena Mazzone; Bakri Elsheikh; Julaine Florence; Linda S Hynan; Susan T Iannaccone; Leslie L Nelson; Shree Pandya; Michael Rose; Charles Scott; Reza Sadjadi; Mackensie A Yore; Cynthia Joyce; John T Kissel
Journal:  Muscle Nerve       Date:  2013-07-26       Impact factor: 3.217

3.  Adiposity is increased among high-functioning, non-ambulatory patients with spinal muscular atrophy.

Authors:  Douglas M Sproule; Jacqueline Montes; Sally Dunaway; Megan Montgomery; Vanessa Battista; Dorcas Koenigsberger; Bill Martens; Wei Shen; Mark Punyanitya; Maryjane Benton; Hailly Butler; Jayson Caracciolo; Eugenio Mercuri; Richard Finkel; Basil Darras; Darryl C De Vivo; Petra Kaufmann
Journal:  Neuromuscul Disord       Date:  2010-06-17       Impact factor: 4.296

4.  Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy.

Authors:  Kristin J Krosschell; Charles B Scott; Jo Anne Maczulski; Aga J Lewelt; Sandra P Reyna; Kathryn J Swoboda
Journal:  Muscle Nerve       Date:  2011-06-22       Impact factor: 3.217

Review 5.  Spinal muscular atrophy.

Authors:  Maryam Oskoui; Petra Kaufmann
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

6.  Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study.

Authors:  Kristin J Krosschell; Michael Bosch; Leslie Nelson; Tina Duong; Linda P Lowes; Lindsay N Alfano; Danielle Benjamin; Terri B Carry; Ginger Devine; Carolyn Kelley; Rebecca Gadekan; Elizabeth C Malkus; Amy Pasternak; Stephanie Provance-Orr; Lynne Roemeiser-Logan; Alina Nicorici; Donata Trussell; Sally Dunaway Young; Jennifer R Fetterman; Jacqueline Montes; Penny J Powers; Rebecca Quinones; Janet Quigley; Christopher S Coffey; Jon W Yankey; Amy Bartlett; John T Kissel; Stephen J Kolb
Journal:  J Neuromuscul Dis       Date:  2018

7.  Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial.

Authors:  Andreea Mihaela Seferian; Amélie Moraux; Aurélie Canal; Valérie Decostre; Oumar Diebate; Anne Gaëlle Le Moing; Teresa Gidaro; Nicolas Deconinck; Frauke Van Parys; Wendy Vereecke; Sylvia Wittevrongel; Mélanie Annoussamy; Michèle Mayer; Kim Maincent; Jean-Marie Cuisset; Vincent Tiffreau; Severine Denis; Virginie Jousten; Susana Quijano-Roy; Thomas Voit; Jean-Yves Hogrel; Laurent Servais
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

8.  Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.

Authors:  Anne M Connolly; Julaine M Florence; Mary M Cradock; Elizabeth C Malkus; Jeanine R Schierbecker; Catherine A Siener; Charlie O Wulf; Pallavi Anand; Paul T Golumbek; Craig M Zaidman; J Philip Miller; Linda P Lowes; Lindsay N Alfano; Laurence Viollet-Callendret; Kevin M Flanigan; Jerry R Mendell; Craig M McDonald; Erica Goude; Linda Johnson; Alina Nicorici; Peter I Karachunski; John W Day; Joline C Dalton; Janey M Farber; Karen K Buser; Basil T Darras; Peter B Kang; Susan O Riley; Elizabeth Shriber; Rebecca Parad; Kate Bushby; Michelle Eagle
Journal:  Neuromuscul Disord       Date:  2013-05-28       Impact factor: 4.296

9.  Phase II open label study of valproic acid in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; Charles B Scott; Sandra P Reyna; Thomas W Prior; Bernard LaSalle; Susan L Sorenson; Janine Wood; Gyula Acsadi; Thomas O Crawford; John T Kissel; Kristin J Krosschell; Guy D'Anjou; Mark B Bromberg; Mary K Schroth; Gary M Chan; Bakri Elsheikh; Louise R Simard
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240

10.  Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials.

Authors:  Eugenio Mercuri; Richard Finkel; Jacqueline Montes; Elena S Mazzone; Maria Pia Sormani; Marion Main; Danielle Ramsey; Anna Mayhew; Allan M Glanzman; Sally Dunaway; Rachel Salazar; Amy Pasternak; Janet Quigley; Marika Pane; Maria Carmela Pera; Mariacristina Scoto; Sonia Messina; Maria Sframeli; Gian Luca Vita; Adele D'Amico; Marleen van den Hauwe; Serena Sivo; Nathalie Goemans; Petra Kaufmann; Basil T Darras; Enrico Bertini; Francesco Muntoni; Darryl C De Vivo
Journal:  Neuromuscul Disord       Date:  2015-12-03       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.